The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.
These are the top news items from the 2023 Revolutionizing Atopic Dermatitis (RAD) meeting, which took place in Washington, DC, from April 29 to May 1.
A panel held at RAD 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the RAD fifth annual conference.
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discussed treatment approaches for AD of the face in infancy.